Microscopy & Imaging

Latest
Microscopy & Imaging

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in clinical trial

Qureight’s Fibr8 is being used a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791

Subscribe to our Newsletter

© 2026 Setform Limited.